期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

益生菌对炎症性肠病的治疗作用和机制 被引量：8

Therapeutic effect and mechanism of probiotics on inflammatory bowel disease
下载PDF
导出
摘要 炎症性肠病包括溃疡性结肠炎和克罗恩病.炎症性肠病患者肠道内存在茵群失调,若给患者补充正常细菌即益生菌,使肠道内菌群失调得到纠正,可使病情缓解.益生菌能改变肠道菌群比例、转化某些肠内物质、提高肠上皮的屏障功能、防止肠细菌易位以及通过调节细胞因子减轻炎症.本文对益生菌以上作用及机制作一综述. Inflammatory bowel disease （IBD） includes ulcerative colitis （UC） and Crohn＇s disease （CD）. Many studies demonstrate an involvement of intestinal microflora in the pathogenesis of IBD. Tissue damages can result from dysregulated immune response to intestinal bacteria in genetically susceptible individuals. Therefore, alteration of the intestinal microflora may represent a feasible therapeutic approach for IBD. Probiotics can change the proportion of intestinal microflora, improve the function of intestinal epithelial barrier, prevent intestinal bacterial translocation and alleviate the inflammation degree. In this article, we reviewed the effect of probiotics in the treatments of IBD and its mechanism.
作者 杨明 韩真
机构地区 皖南医学院弋矶山医院消化内科
出处 《世界华人消化杂志》 CAS 北大核心 2007年第14期1634-1638,共5页 World Chinese Journal of Digestology
关键词 益生菌 炎症性肠病 肠道菌群 Probiotics, Inflammatory bowel disease Intestinal microflora
分类号 R574 [医药卫生—消化系统]
  • 相关文献

参考文献34

  • 1Fuller R.Probiotics in man and animals.J Appl Bacteriol 1989; 66:365-378
  • 2Kruis W,Fric P,Pokrotnieks J,Lukas M,Fixa B,Kascak M,Kamm MA,Weismueller J,Beglinger C,Stolte M,Wolff C,Schulze J.Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.Gut 2004; 53:1617-1623
  • 3Furrie E,Macfarlane S,Kennedy A,Cummings JH,Walsh SV,O'neil DA,Macfarlane GT.Synbiotic therapy (Bifidobacterium longum/Synergy 1)initiates resolution of inflammation in patients with active ulcerative colitis:a randomised controlled pilot trial.Gut 2005; 54:242-249
  • 4Bibiloni R,Fedorak RN,Tannock GW,Madsen KL,Gionchetti P,Campieri M,De Simone C,Sartor RB.VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.Am J Gastroenterol 2005; 100:1539-1546
  • 5Gionchetti P,Rizzello F,Venturi A,Brigidi P,Matteuzzi D,Bazzocchi G,Poggioli G,Miglioli M,Campieri M.Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis:a double-blind,placebo-controlled trial.Gastroenterology 2000; 119:305-309
  • 6Gionchetti P,Rizzello F,Helwig U,Venturi A,Lammers KM,Brigidi P,Vitali B,Poggioli G,Miglioli M,Campieri M.Prophylaxis of pouchitis onset with probiotic therapy:a double-blind,placebo-controlled trial.Gastroenterology 2003; 124:1202-1209
  • 7Mimura T,Rizzello F,Helwig U,Poggioli G,Schreiber S,Talbot IC,Nicholls RJ,Gionchetti P,Campieri M,Kamm MA.Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.Gut 2004; 53:108-114
  • 8Schultz M,Timmer A,Herfarth HH,Sartor RB,Vanderhoof JA,Rath HC.Lactobacillus GG in inducing and maintaining remission of Crohn's disease.BMC Gastroenterol 2004; 4:5
  • 9Bousvaros A,Guandalini S,Baldassano RN,Botelho C,Evans J,Ferry GD,Goldin B,Hartigan L,Kugathasan S,Levy J,Murray KF,Oliva-Hemker M,Rosh JR,Tolia V,Zholudev A,Vanderhoof JA,Hibberd PL.A randomized,double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease.Inflamm Bowel Dis 2005; 11:833-839
  • 10Marteau P,Lemann M,Seksik P,Laharie D,Colombel JF,Bouhnik Y,Cadiot G,Soule JC,Bourreille A,Metman E,Lerebours E,Carbonnel F,Dupas JL,Veyrac M,Coffin B,Moreau J,Abitbol V,Blum-Sperisen S,Mary JY.Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease:a randomised,double blind,placebo controlled GETAID trial.Gut 2006; 55:842-847

二级参考文献47

  • 1白爱平,欧阳钦.益生菌治疗炎症性肠病的机制[J].胃肠病学,2005,10(4):240-242. 被引量：33
  • 2Lievin-Le Moal V,Amsellem R,Servin AL,Coconnier MH.Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells.Gut,2002,50:803～811.
  • 3Resta-Lenert S,Barrett KE.Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichiacoli (EIEC).Gut,2003,52:988～997.
  • 4Korzenik JR,Podolsky DK.Evolving knowledge and therapy of inflammatory bowel disease.Nat Rev Drug Discov.2006,5:197～209.
  • 5Mack DR,Ahrne S,Hyde L,Wei S,Hollingsworth MA.Extracellular MUC3 mucin secretion follows adherence of lactobacillus strains to intestinal epithelial cells in vitro.Gut,2003,52:827-833.
  • 6Prantera C.Probiotics for Crohn's disease:what have we learned? Gut,2006; 55:757～759.
  • 7Boudeau J,Glasser AL,Julien S,Colombel JF,Darfeuille-Michaud A.Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent invasive E.coli strains isolated from patients with Crohn's disease.Aliment Pharmacol Ther,2003,18:45～56.
  • 8Karo K,Mizuno S,Umesaki Y,Ishii Y,Sugitani M,Imaoka A,Otsuka M,Hasunuma O,Kurihara R,Iwasaki A,Arakawa Y.Randomized placebo-controlled trial assessing the effect of bifidobacteria fermented milk on active ulcerative colitis.Aliment Pharmacol Ther,2004,20:1133～1141.
  • 9Is Ishikawa H,Akedo I,Umesaki Y,Tanaka R,Imaoka A,Otani T.Randomized controlled trial of the effect of bifidobacteria fermented milk on ulcerative colitis.J Am Coll Nutr,2003,22:56～63.
  • 10Furrie E,Macfarlane S,Kennedy A,Cummings JH,Walsh SV,O'neil DA,Macfarlane GT.Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis:a randomised controlled pilot trial.Gut,2005,54:242～249.

共引文献32

同被引文献86

引证文献8

二级引证文献58

世界华人消化杂志
2007年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部